Effect of Trinucleotide Repeat Expansion on the Expression of TCF4 mRNA in Fuchs’ Endothelial Corneal Dystrophy

Naoki Okumura,1 Ryosuke Hayashi,1 Masakazu Nakano,2 Kengo Yoshii,3 Kei Tashiro,2 Takahiko Sato,4 Derek J. Blake,5 Ross Alleff,5 Malinda Butz,7 Edward W. Highsmith,7 Eric D. Wieben,6 Michael P. Fautsch,8 Keith H. Baratz,8 Yuya Komori,1 Makiko Nakahara,1 Theofilos Tourtas,9 Ursula Schlötzer-Schrehardt,9 Friedrich Kruse,9 and Noriko Koizumi1

1Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan
2Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan
3Department of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan
4Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
5Department of Psychology and Clinical Neurosciences, Cardiff University, United Kingdom
6Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States
7Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States
8Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
9Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany

Correspondence: Noriko Koizumi, Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe 610-0321, Japan; nkoizumi@mail.doshisha.ac.jp.

Submitted: September 15, 2018 Accepted: December 10, 2018


Purpose. CTG trinucleotide repeat (TNR) expansion is frequently found in transcription factor 4 (TCF4) in Fuchs’ endothelial corneal dystrophy (FECD), though the effect of TNR expansion on FECD pathophysiology remains unclear. The purpose of this study was to evaluate the effect of TNR expansion on TCF4 expression in corneal endothelium of patients with FECD.

Methods. Peripheral blood DNA and Descemet membrane with corneal endothelium were obtained from 203 German patients with FECD. The CTG TNR repeat length in TCF4 was determined by short tandem repeat (STR) assays and Southern blotting using genomic DNA. Genotyping of rs613872 in TCF4 was performed by PCR. TCF4 mRNA levels in corneal endothelium were evaluated by quantitative PCR using three different probes. Control corneal endothelial samples were obtained from 35 non-FECD subjects.

Results. The STR assay and Southern blotting showed that 162 of the 203 patients with FECD (80%) harbored CTG trinucleotide repeat lengths larger than 50. Quantitative PCR using all three probes demonstrated that TCF4 mRNA is significantly upregulated in the corneal endothelium of patients with FECD, regardless of the presence of TNR expansion. However, the length of the TNR tended to show a positive correlation with TCF4 expression level. No correlation was shown between the genotype of TCF4 SNP, rs613872, and the level of TCF4 expression.

Conclusions. Our findings showed that TCF4 mRNA is upregulated in the corneal endothelium of patients with FECD. Further studies on the effects of TCF4 upregulation on corneal endothelial cell function will aid in understanding the pathophysiology of FECD.

Keywords: Fuchs’ endothelial corneal dystrophy, TCF4, trinucleotide repeat

Fuchs’ endothelial corneal dystrophy (FECD) is characterized by a loss of corneal endothelial cells that is associated with a clinically phenotypical hallmark of guttae, which are excrescences of Descemet membrane formed by abnormal deposition of extracellular matrix. As the corneal endothelium maintains corneal transparency by regulating the degree of hydration in the corneal stroma, severe corneal endothelial cell loss due to FECD induces corneal haziness, resulting in vision loss.1,2

FECD is a hereditary disease with a typically autosomal dominant pattern of inheritance, though the genetic basis is not fully elucidated.1,2 In 2012, Wieben and colleagues3 reported that expansion of a trinucleotide repeat (TNR) in the third intron of TCF4 was strongly associated with FECD, and the sensitivity and specificity for identifying FECD in their patient cohort was 79% and 96%, respectively.3 They postulated that FECD is a TNR disorder within the non-coding region, with similarities to Friedreich’s ataxia, myotonic dystrophy type 1, and fragile X syndrome.3 Subsequently, other researchers have replicated this strong association in other independent cohorts such as Caucasian, Indian, Chinese, and Japanese.4–9

Simple sequence repeats exist throughout the human genome, but expansion of the TNR was discovered as causal genetic basis in patients with spinal and bulbar muscle atrophy in 1991.10 Since the first discovery of TNR expansion disease,
more than 20 disorders have been identified, all of which are neurologic or neuromuscular degenerations.\textsuperscript{11–13} TNR expansion disease can be categorized into two groups: TNR expansion disease occurring in coding regions or TNR expansion disease occurring in noncoding regions. Diseases with CAG repeat expansion in coding regions induce polyglutamine tracts, which generate toxic proteins. By contrast, TNR expansion in noncoding regions in triplet repeat disorders can suppress or enhance gene transcription of the surrounding gene, produce antisense RNA, alter the RNA splicing pattern by sequestration of splicing factors, result in intron retention, and/or have repeat-associated non-ATG (RAN) translation, and eventually play an essential role in pathophysiology.\textsuperscript{13–19}

Elucidation of the effect of TNR expansion on expression of the gene harboring the expansion is beneficial for understanding the pathophysiology of triplet repeat diseases; however, the effect of TNR expansion on the transcription of TCF4 is not well elucidated in FECD. In the current study, we collected peripheral blood samples from 398 German patients with FECD, as well as the Descemet membrane and associated corneal endothelium when these patients underwent Descemet membrane endothelial keratoplasty (DMEK). We subsequently evaluated whether expression levels in the corneal endothelium were altered by TNR expansion in TCF4 in samples derived from 203 of these FECD subjects.

**Materials and Methods**

**Ethics Statement**

Institutional review board approvals for research involving human subjects were obtained from the Friedrich-Alexander University Erlangen-Nürnberg, Doshisha University, Kyoto Prefectural University of Medicine, and the Mayo Clinic. The human tissue was handled under the guidelines based on the tenets of the Declaration of Helsinki. Non-FECD human donor corneas were obtained from SightLife (Seattle, WA, USA).

**Study Participants**

The 398 patients with FECD who were scheduled for DMEK were recruited between October 2013 and September 2015 at the Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nürnberg. After informed consent, peripheral blood samples were collected and Descemet membranes with corneal endothelial cells (CECs) were obtained during DMEK. For samples utilized in this study, genomic DNA obtained from peripheral blood required a DNA concentration of \( \geq 3.0 \mu g/mL \) and total RNA isolated from CEC’s required an RNA integrity number \((RIN) \geq 5.2 \). Of the samples from the 398 patients, 203 fulfilled the quality criteria for genomic DNA and total RNA isolation. As controls, genomic DNA was isolated from donor corneas (corneal stroma) of 35 non-FECD subjects, and cDNA was synthesized from the CECs of the same 35 non-FECD subjects.

**Preparation of Genomic DNA From Peripheral Blood and Donor Corneas**

Genomic DNA was isolated from 200 \( \mu L \) of peripheral blood of FECD subjects or non-FECD donor corneal stromas with a commercial DNA kit (DNasey Blood & Tissue Kit; Qiagen, Hilden, Germany). Briefly, peripheral blood and stromas were lysed with protease K, the lysate was applied to spin columns (DNasey Mini Spin Columns; Qiagen), and the columns were washed with ethanol and then with buffer to elute the genomic DNA. The amount and quality of each isolated DNA sample were analyzed by UV spectrophotometry (NanoDrop; NanoDrop Technologies, Wilmington, DE, USA). As a control, genomic DNA was isolated from corneal stromas of the 35 non-FECD donor corneas.

**Preparation of Total RNA and Synthesis of cDNA From Corneal Endothelium**

An RNA extraction kit (RNasey Mini Kit; Qiagen) was used to extract total RNA from the corneal endothelium obtained from the 203 FECD patients during DMEK. Briefly, Descemet membranes with corneal endothelium were lysed, and the lysate was applied to spin columns (Qiagen) with ethanol. The total RNA was eluted from columns, and cDNA was synthesized using a master mix (SuperScript VILO Master Mix; Thermo Fisher Scientific Inc., Waltham, MA, USA). As a control, Descemet membranes with corneal endothelium were peeked from the 35 non-FECD donor corneas, and cDNA was synthesized from the extracted total RNA.

**Evaluation of CTG TNR Length**

The CTG TNR length in \( \text{TCF4} \) was evaluated by a short tandem repeat (STR) assay, as described previously.\textsuperscript{4} Briefly, PCR was performed for the CTG repeat region using one fluoroscently labeled primer. The size of the products was determined by capillary electrophoresis on a DNA analyzer (ABI 3730x; Applied Biosystems, Foster City, CA). Samples that showed a single signal by STR were further analyzed by Southern blotting (described previously)\textsuperscript{7} using unamplified genomic DNA to determine if these samples carried a large repeat.

**Quantitative Real-Time PCR**

Quantitative real-time PCR (qPCR) was performed with a real-time PCR system (QuantStudio 3; Applied Biosystems). All samples were analyzed in duplicate with a program of 95°C for 20 seconds and 40 cycles of 95°C for 1 second and 60°C for 20 seconds. For quantification, standard curves were run in parallel using serial dilutions (5–5\(^{10}\) copies) of cDNA of cultured immortalized human CECs, as described previously.\textsuperscript{20} Ratios relative to \( \text{GAPDH} \) were calculated for normalization of gene expression levels. In this study, qPCR was based on a hydrolysis probe system (Taqman; Thermo Fisher Scientific, Inc.). The hydrolysis probes (Thermo Fisher Scientific, Inc.) were for \( \text{TCF4}; \) \( \text{Hs 00971338_m1; Hs00162613_m1; Hs00972432_m1; } \) and predevelopment human \( \text{GAPDH} \) (Thermo Fisher Scientific, Inc., Inc.).

**Genotyping**

Genotyping of rs613872 in \( \text{TCF4} \) was performed by PCR using the following primers: forward primer \(-5’-\text{aggg-3’}\) and reverse primer \(-5’-\text{gaggg-3’}\). PCR reactions were carried out with Ex Taq DNA polymerase (Takara Bio Inc., Otsu, Japan) under the following conditions: 1 cycle of denaturation at 94°C for 2 minutes followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and elongation at 72°C for 30 seconds. Upon completion of the 35 cycles, a final elongation was performed at 72°C for 5 minutes. The PCR products were separated by electrophoresis on 2% agarose gels in Tris-acetate buffer, stained with ethidium bromide, imaged with a luminescence imager (LAS4000; Fuji Film, Tokyo, Japan), and then extracted from the agarose gels using the a commercial gel and a PCR cleanup system (Wizard SV Gel; Promega, Madison, WI, USA). A terminator cycle sequencing
**TABLE. Demographic Data of Patients With FECD and non-FECD Controls**

<table>
<thead>
<tr>
<th>CTG Repeat</th>
<th>Control (n = 35)</th>
<th>No Expansion</th>
<th>CTG &lt; 50</th>
<th>Expansion</th>
<th>CTG ≥ 50</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>58.0 ± 13.1</td>
<td>68.9 ± 10.2</td>
<td>69.8 ± 9.4</td>
<td>&lt;0.01*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(21, 92)</td>
<td>(42, 90)</td>
<td>(34, 87)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>28</td>
<td>11</td>
<td>74</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>7</td>
<td>30</td>
<td>88</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data represent the mean ± SD (minimum, maximum).

* P value of Student’s t-test for case and control age comparisons.
† P value of Fisher exact test for case and control sex comparisons.

In the FECD subjects (11 males and 30 females with CTG < 50, and 74 males and 88 females with CTG ≥ 50).

### Expression Levels of TCF4 in the Corneal Endothelium of Patients With FECD

We used qPCR to evaluate the expression level of *TCF4* in the corneal endothelium of patients with FECD. As *TCF4* has multiple alternatively spliced isoforms, we used three probes (Thermo Fisher Scientific, Inc.) for qPCR that are all contained within the canonical *TCF4* transcript (Refseq: NM_001083962) that encodes *TCF4*-B (Fig. 1). The expression level of *TCF4* determined by Hs00971338 was significantly higher in patients with FECD with or without CTG TNR expansion >50 than in non-FECD subjects (control: 7.2 ± 4.8; FECD without expansion: 22.3 ± 29.9; and FECD without expansion: 47.4 ± 46.3; P < 0.01). The *TCF4* level was also significantly higher in FECD with expansion than in FECD without expansion (P < 0.01; Fig. 2A). The expression level of *TCF4* determined by Hs00162613 was significantly higher in patients with FECD with or without CTG TNR expansion >50 than in non-FECD subjects (control: 2.2 ± 1.3, FECD without expansion: 4.5 ± 1.6, and FECD without expansion: 4.3 ± 1.5, P < 0.01); however, no statistically significant difference was observed in *TCF4* levels between FECD with expansion and FECD without expansion (Fig. 2B). The expression level of *TCF4* determined by Hs00972432 was higher in FECD with or without CTG TNR expansion >50 than in non-FECD subjects (control: 2.8 ± 3.1, FECD without expansion: 6.7 ± 4.9, and FECD without expansion: 10.8 ± 8.2), but only the *TCF4* level in FECD with expansion showed statistical significance when compared with the control subjects (P < 0.01). Consistent with the *TCF4* level determined by Hs00971338, the *TCF4* level determined by Hs00972432 was significantly higher in FECD with expansion than in FECD without expansion (P < 0.01; Fig. 2C).

### Effect of CTG Repeat Length or Genotype on TCF4 Expression Level

We evaluated whether the CTG TNR length or the genotype of the single nucleotide polymorphism (SNP) rs613872 in *TCF4* correlated with *TCF4* expression levels in FECD. Spearman’s correlation coefficient by rank test revealed a weak positive correlation between CTG TNR length in genomic DNA from peripheral blood and the expression level of *TCF4* in the corneal endothelium determined by Hs00971338 (ρ = 0.24, P < 0.01) and Hs00972432 (ρ = 0.22, P < 0.01; Figs. 3A, 3C). Conversely, the CTG TNR length did not show significant correlation with expression level of *TCF4* determined by Hs00162613 (Fig. 3B). We also evaluated the effect of other potent confounders, including sex and age, on the expression level of *TCF4*. The expression level of *TCF4* (normalized by expression level of GAPDH) in the corneal endothelium, determined by Hs00971338, was 39.1 ± 49.7 in males and
35.4 ± 36.2 in females ($P = 0.77$). Likewise, expression level of $TCF4$ was similar level between sexes, at 3.9 ± 1.6 in males and 4.1 ± 1.4 in females, determined by Hs00971338 ($P = 0.29$), and 8.1 ± 6.7 in males and 9.7 ± 8.6 in females ($P = 0.10$), determined by Hs00972432. Since Wirgenes and colleagues previously reported that age showed a very weak positive correlation with $TCF4$ mRNA levels in blood,21 we also evaluated the correlation between age and the expression level of $TCF4$ in the corneal endothelium. Spearman's correlation coefficient by rank test did not show a significant correlation with the expression level of $TCF4$, determined by Hs00162613 and Hs00972432, though the expression level determined by Hs00971338 revealed a weak positive correlation with marginal statistical significance (Supplementary Fig. S1).

Consistent with previous reports confirming the “G” risk allele in rs613872,22 genotyping results showed that the genotype of this $TCF4$ SNP was TT:30 (15%), TG:140 (69%), and GG:33 (16%) in German FECD cases, while it was TT:27 (77%), TG:7 (20%), and GG:1 (3%) in the control subjects ($P < 0.01$). No correlation was found between the genotype of $TCF4$
SNP rs613872 and expression level of TCF4 determined by all three probes (Figs. 4A–C).

**DISCUSSION**

Diseases with TNR expansion in non-coding regions typically cause a loss of gene function or toxic effects at the mRNA level, but their pathophysiology varies depending on the type and the location of the TNR. For example, myotonic dystrophy type 1 harbors CTG repeats within the 3' UTR in the myotonic dystrophy protein kinase (DMPK) gene. These CTG repeats in DMPK gene lead to the formation of transcript aggregates in the nucleus (referred to as RNA foci) that sequester RNA-binding proteins, resulting in a spliceopathy of downstream effector genes. In Friedreich's ataxia, a GAA repeat expansion in the first intron of the frataxin gene suppresses the frataxin mRNA and protein expression, leading to impaired mitochondrial iron transport. Likewise, a CGG repeat expansion in the 5'UTR of the fragile X mental retardation gene (FMR1) represses transcription by CpG hypermethylation of the FMR1 promoter. However, suppression of gene expression by repeats is not always identified among triplet repeat expansion diseases. In spinocerebellar ataxia type 12, overexpression of the PPP2R2B gene is linked to the length of a CAG TNR expansion, suggesting this is involved in the underlying pathophysiology. These reports encouraged us to conduct the current study to answer the simple but fundamental question: "Does CTG repeat expansion in FECD alter the expression of TCF4 mRNA level in the corneal endothelium?"

Studies reporting the expression of TCF4 in patients with FECD have resulted in contrasting conclusions. For example, Mootha and colleagues reported no alterations in TCF4 levels in the corneal endothelium of FECD patients when compared to control subjects. Likewise, Oldak and colleagues analyzed the corneal endothelium from 40 FECD cases and 23 control subjects, and showed similar expression levels of TCF4 in both groups and stable TCF4 levels regardless of the risk allele of rs613872. By contrast, Foja and colleagues reported decreased TCF4 levels in the corneal endothelium of FECD patients in their examination of 6 FECD patients with TNR expansion >50 and 5 controls with TNR expansion <50.

In the current study, we demonstrated a significantly higher expression of TCF4 at the mRNA level in the corneal endothelium of patients with FECD compared to normal...
controls. However, *TCF4* has multiple alternatively spliced variants and the variants expressed in corneal endothelium have not been elucidated. Therefore, we examined the splicing variants of *TCF4* at three different loci that correlated with conserved motifs in the TCF4 protein sequence, and we found upregulation of *TCF4* transcription in the patients with FECD, even in the patients without TNR expansion. Interestingly, the CTG repeat length, but not the presence of risk allele G in rs613872, tended to correlate with the TCF4 mRNA level. Further studies will be necessary to address whether expansion upregulates TCF4 transcription and if the increase in TCF4 transcription has toxic effects in the corneal endothelium.

*TCF4* encodes numerous transcripts, but the probe set Hs00971338, located proximally (5') to the TNR, will only amplify the canonical TCF4 transcript encoding TCF4-B. Interestingly, the qPCR results showed that levels of the TCF4-B transcript are significantly elevated in FECD cases with repeat expansions when compared to cases without an expansion and controls. This finding may indicate a differential effect of the FECD-associated TNR in *TCF4* on the expression of the different TCF4 transcripts in CECs.

*TCF4* is a basic helix-loop-helix (bHLH) transcription factor that plays an important role in various developmental processes. One large-scale genome-wide association study (GWAS) identified *TCF4* as the first gene to show a strong association with schizophrenia. *TCF4* variants have also shown associations with primary sclerosing cholangitis and Pitt-Hopkins syndrome, as well as with FECD. The role of TCF4 in the context of disease pathogenesis still remains unclear, but involvement in the regulation of the epithelial-mesenchymal transition (EMT) was described in certain cell types. For instance, the overexpression of TCF4 in kidney cells induced EMT by upregulation of EMT-related markers. In human neuroblastoma cells, genome-wide expression profiling showed that knockdown of TCF4 altered multiple signaling pathways related to the EMT and to transforming growth factor-β (TGF-β), an essential mediator of the EMT. We established a cell model from patients with FECD and showed that TGF-β upregulates EMT-related genes, thereby inducing

Figure 4. Correlation between the genotype of *TCF4* SNP rs613872 and *TCF4* expression level. Genotyping of rs613872 in *TCF4* was performed by PCR. No statistically significant correlation was revealed by the Steel-Dwass test between the genotype of *TCF4* SNP rs613872 and the expression level of *TCF4* determined by three probes: (A) Hs00971338, (B) Hs001612613, and (C) Hs00972432.
TCF4 Expression in Fuchs’ Endothelial Corneal Dystrophy

In conclusion, we have demonstrated that TCF4 mRNA is upregulated in patients with FECD, regardless of the presence or absence of TNR expansion, but the length of the TNR in cases with expansion tended to correlate with the TCF4 expression level. These findings suggest the possibility that upregulation of TCF4 plays a central role in FECD. However, further studies are needed to identify the “missing link” between the increases in TCF4 mRNA and the proposed pathophysiology that appears to involve upregulation of TGF-β signaling, disruption of protein loading in the endoplasmic reticulum.

Acknowledgments
The authors thank Seiichiro Sugita (Sugita Eye Hospital) for providing research materials, and Emi Ueda and Kyoko Watanabe for technical assistance.

Supported by the Program for the Strategic Research Foundation at Private Universities from MEXT (NK, NO), National Institutes of Health grant EY26490 (MPF) and the Robert Waller Career Development Award (KHJ).

Disclosure: N. Okamura, None; R. Hayashi, None; M. Nakano, None; K. Yoshii, None; K. Tashiro, None; T. Sato, None; D.J. Blake, None; R. Aleff, None; M. Butz, None; E.W. Highsmith, None; E.D. Wieben, None; M.P. Faustch, None; K.H. Baratz, None; Y. Komori, None; M. Nakahara, None; T. Tourtas, None; U. Schötzler-Schrehardt, None; F. Kruse, None; N. Koizumi, None

References


